MedPath
Found 28 clinical trials|View Analysis
Sort by:

The Effect of an Online ACT Intervention on Meaning-Making Process in Cancer Patients Following Hematopoietic Cell Transplantation

Not Applicable
Recruiting
Conditions
Hematopoietic Cell Transplantation Recipient
Acceptance and Commitment Therapy
Interventions
Behavioral: Acceptance and Commitment Therapy
Behavioral: Education
First Posted Date
2024-02-20
Last Posted Date
2024-05-16
Lead Sponsor
University of Social Sciences and Humanities, Warsaw
Target Recruit Count
192
Registration Number
NCT06266182
Locations
🇵🇱

Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Department of Bone Marrow Transplantation and Oncohematology, Gliwice, Poland

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

Phase 1
Recruiting
Conditions
Living Donor Kidney Transplantation
Interventions
Biological: Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
First Posted Date
2019-05-09
Last Posted Date
2023-11-22
Lead Sponsor
Stanford University
Target Recruit Count
22
Registration Number
NCT03943238
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

🇺🇸

Nothwestern University, Chicago, Illinois, United States

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Phase 2
Completed
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Osteoporosis
Osteopenia
Interventions
Biological: Denosumab
First Posted Date
2019-04-24
Last Posted Date
2024-03-13
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
30
Registration Number
NCT03925532
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Phase 1
Withdrawn
Conditions
CD22 Positive
Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells
Recurrent B Acute Lymphoblastic Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Blasts 5 Percent or More of Peripheral Blood White Cells
Lymphoblasts 20 Percent or More of Peripheral Blood White Cells
Refractory B Acute Lymphoblastic Leukemia
Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Interventions
Biological: Inotuzumab Ozogamicin
Other: Quality-of-Life Assessment
Drug: Vincristine Sulfate Liposome
First Posted Date
2019-02-22
Last Posted Date
2022-01-28
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT03851081
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Phase 2
Recruiting
Conditions
Acute Biphenotypic Leukemia
Acute Leukemia
Acute Leukemia of Ambiguous Lineage
Acute Lymphoblastic Leukemia
Acute Undifferentiated Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Blastic Plasmacytoid Dendritic Cell Neoplasm
Blasts Under 25 Percent of Bone Marrow Nucleated Cells
Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Mixed Phenotype Acute Leukemia
Interventions
Radiation: Total-Body Irradiation
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Busulfan
Drug: Tacrolimus
Procedure: Allogeneic Bone Marrow Transplantation
Drug: Methotrexate
Procedure: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation
Procedure: Echocardiography
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
First Posted Date
2018-12-19
Last Posted Date
2024-11-14
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
68
Registration Number
NCT03779854
Locations
🇺🇸

Children's Hospital of Los Angeles, Los Angeles, California, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 7 locations

High Dose Vitamin a in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant

Not Applicable
Recruiting
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Interventions
Dietary Supplement: Vitamin A Compound
First Posted Date
2018-10-25
Last Posted Date
2025-01-03
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
130
Registration Number
NCT03719092
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Early Phase 1
Recruiting
Conditions
Donor
Cytomegalovirus
Solid Organ Transplantation Recipient
Adenovirus
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Interventions
Biological: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Biological: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
First Posted Date
2018-09-11
Last Posted Date
2024-03-08
Lead Sponsor
Sumithira Vasu
Target Recruit Count
20
Registration Number
NCT03665675
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

Conditions
Hematopoietic Cell Transplantation Recipient
Malignant Neoplasm
Benign Neoplasm
Bone Marrow Transplantation Recipient
First Posted Date
2018-08-13
Last Posted Date
2024-08-16
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT03626285
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1
Completed
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Interventions
First Posted Date
2018-07-26
Last Posted Date
2024-12-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
29
Registration Number
NCT03600155
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1
Conditions
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Refractory Follicular Lymphoma
Refractory Marginal Zone Lymphoma
Refractory Non-Hodgkin Lymphoma
Refractory Transformed Indolent Non-Hodgkin Lymphoma
Hematopoietic Cell Transplantation Recipient
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Interventions
First Posted Date
2018-07-11
Last Posted Date
2021-10-06
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
19
Registration Number
NCT03583424
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath